Core Insights - CareCloud, Inc. has announced that Affinity Urgent Care has selected its Wellsoft emergency department information system, marking CareCloud's entry into the urgent care market, which consists of approximately 11,000 facilities in the U.S. [1] Company Overview - CareCloud is a leader in healthcare technology and AI-powered solutions, providing a suite of services that enhance financial and operational performance, streamline clinical workflows, and improve patient experiences [8]. - The company has over 40,000 providers relying on its solutions, which include revenue cycle management, practice management, electronic health records, and patient experience management [8]. Product Details - Wellsoft, acquired by CareCloud in August 2025, is recognized as a category leader in emergency medicine and is designed to meet the clinical demands of urgent care facilities [2][3]. - The platform offers emergency-grade documentation, optimized throughput, and integrated diagnostics, enabling urgent care operators to manage high patient volumes and complex clinical needs effectively [5][6]. Market Context - Urgent care centers are increasingly required to deliver emergency-level medical care with the convenience of retail services, creating a significant opportunity for solutions like Wellsoft [3][4]. - The urgent care market is evolving, with demand patterns accelerating, necessitating clinics to operate in a hybrid role that combines high-volume outpatient care with the unpredictability of emergency department acuity [4]. Strategic Importance - The partnership with Affinity is seen as an early indicator of a larger national opportunity for CareCloud, as urgent care providers face challenges such as staffing complexity and rising patient expectations [3]. - Wellsoft's capabilities allow urgent care providers to enhance clinical performance and financial outcomes, supporting their growth without compromising quality [5].

Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025Annual Nociscan scan volumes increased 69% year-over-year in 2025Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, extending cash runway into 2027 and providing strategic flexibility for continued commercial growthCompany aims to enroll approximately 25% of patients in CLARITY trial by the end of Q2 2026, with the first internal readout on interim data anticipated in Q3 2026 BROOMFIELD, Colo., Jan. 08, 2026 (GL ...

OpenAI周三推出ChatGPT Health，允许用户将医疗记录和健康应用安全连接至这一人工智能聊天机器 人。这标志着这家AI初创公司正式进军医疗健康领域，试图将ChatGPT打造成覆盖用户生活各个方面 的"个人超级助手"。 OpenAI数据显示，每周有超过2.3亿人在该公司平台上询问健康和保健问题，凸显医疗健康市场需求的 庞大规模。OpenAI最新推出的ChatGPT Health，并非用于诊断和治疗，也不能取代医疗护理，旨在帮助 用户处理日常健康问题，并通过整合用户自身健康信息使ChatGPT的回复更具相关性。 ChatGPT Health将在聊天机器人内设立独立空间，所有文件、对话和连接的应用将与其他聊天记录分开 存储。OpenAI承诺，这些对话不会被用于训练其基础模型，健康空间内的信息和记忆也不会流向外 部。 该功能将首先向小部分早期用户开放以收集反馈，并在未来几周内扩大访问范围。OpenAI已与健康数 据连接基础设施提供商b.well合作，用户还可连接Apple Health、MyFitnessPal、Weight Watchers和实验 室检测初创公司Function等服务。 独立健康空间保护 ...

Life science marketers will be able to better measure the exposed audiences for a more complete, accurate, and transparent view of campaign engagement and effectivenessWALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life science companies reach and engage healthcare professionals (HCPs) and patients, today announced at CES 2026 a data collaboration with Experian, a leading global data and technol ...

Company Overview - Phreesia, Inc. (NYSE:PHR) is a healthcare technology company focused on enhancing patient intake and engagement while streamlining administrative processes in healthcare settings [1][5] - The company operates in a competitive landscape alongside peers such as Health Catalyst, Veracyte, Accolade, Castle Biosciences, and Personalis, each providing unique solutions in the healthcare technology sector [1] Financial Performance - Phreesia's Return on Invested Capital (ROIC) is -12.98%, indicating that the company is not generating returns above its cost of capital [2][5] - The company's Weighted Average Cost of Capital (WACC) is 6.71%, leading to a ROIC to WACC ratio of -1.93, which suggests inefficient capital utilization [2][5] Peer Comparison - Health Catalyst has a ROIC of -16.99% and a WACC of 6.12%, resulting in a ROIC to WACC ratio of -2.78, indicating even less efficient capital utilization than Phreesia [3] - Accolade and Personalis also exhibit negative ROIC to WACC ratios of -2.91 and -3.19, respectively, reflecting similar challenges in generating returns above their cost of capital [3] - Castle Biosciences has a ROIC of -4.44% and a WACC of 8.60%, resulting in a ROIC to WACC ratio of -0.52, which, while still negative, is closer to breaking even compared to other peers [4] Industry Challenges - Overall, Phreesia and its peers face significant challenges in generating sufficient returns to cover their cost of capital, which raises concerns for investors [4]

MANHATTAN, N.Y., Jan. 06, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co., a Manhattan-headquartered investment bank and broker-dealer, today announced that it acted as the exclusive placement agent in connection with iSpecimen Inc.’s (Nasdaq: ISPC) private placement, raising approximately $5.5 million in gross proceeds before fees and expenses. The transaction reflects continued capital markets interest in differentiated healthcare technology platforms that support medical research and discovery. iSpecimen oper ...

MOBILE, Ala. & ARLINGTON, Va.--(BUSINESS WIRE)--TruBridge, Inc. (NASDAQ: TBRG), a leading provider of healthcare technology solutions for rural and community hospitals, and The Health Management Academy (THMA), a leading executive membership and peer-learning organization, today announced the launch of the Rural Health Collaborative, a new initiative designed to support, modernize, and strengthen rural and community hospitals during a critical period for healthcare delivery. Through this collab. ...

Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational requirements to screen and enroll patients in CLARITY First readout on interim data expected after initial cohort of patients achieves 3-month follow up visit in 3Q 2026 BROOMFIELD, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare ...

Core Viewpoint - Claritev Corporation is focused on making healthcare more affordable, transparent, and fair for all, and will present at the 44th Annual J.P. Morgan Healthcare Conference [1] Company Participation - Claritev Corporation will participate in the 44th Annual J.P. Morgan Healthcare Conference [1] - The management presentation is scheduled for Thursday, January 15, 2026, at 7:30 a.m. PT [1] - A live webcast and audio archive of the presentation will be available through the investor relations section of Claritev's website [1]

Tempus AI, Inc. (NASDAQ:TEM) is among the 12 Best Genomics Stocks to Invest In. Canaccord Lowers Price Objective On Tempus AI, Inc. (TEM) TheFly reported on December 22, 2025, that Canaccord reduced the price objective for Tempus AI, Inc. (NASDAQ:TEM) to $80 from $95. The shares were still rated as a buy by analyst Kyle Mikson. As noted by Canaccord, the sector momentum that started in the latter half of 2025 can continue into 2026, based on a preview of its coverage of life science instruments and diagn ...